Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2014 5
2015 1
2016 3
2017 3
2018 5
2019 2
2020 5
2021 2
2022 8
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Jennings D, et al. Among authors: zhu y. Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8. Sci Transl Med. 2022. PMID: 35675433
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Estrada AA, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C. Vissers MFJM, et al. Among authors: zhu y. Clin Transl Sci. 2022 Aug;15(8):2010-2023. doi: 10.1111/cts.13317. Epub 2022 Jun 1. Clin Transl Sci. 2022. PMID: 35649245 Free PMC article. Clinical Trial.
Longitudinal biomarkers in amyotrophic lateral sclerosis.
Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH Jr, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD. Huang F, et al. Among authors: zhu y. Ann Clin Transl Neurol. 2020 Jul;7(7):1103-1116. doi: 10.1002/acn3.51078. Epub 2020 Jun 9. Ann Clin Transl Neurol. 2020. PMID: 32515902 Free PMC article.
PD-L1 Regulates Platelet Activation and Thrombosis via Caspase-3/GSDME Pathway.
Li Y, Xin G, Li S, Dong Y, Zhu Y, Yu X, Wan C, Li F, Wei Z, Wang Y, Zhang K, Chen Q, Niu H, Huang W. Li Y, et al. Among authors: zhu y. Front Pharmacol. 2022 Jun 15;13:921414. doi: 10.3389/fphar.2022.921414. eCollection 2022. Front Pharmacol. 2022. PMID: 35784685 Free PMC article.
In vitro assessment of chemotherapy-induced neuronal toxicity.
Snyder C, Yu L, Ngo T, Sheinson D, Zhu Y, Tseng M, Misner D, Staflin K. Snyder C, et al. Among authors: zhu y. Toxicol In Vitro. 2018 Aug;50:109-123. doi: 10.1016/j.tiv.2018.02.004. Epub 2018 Feb 7. Toxicol In Vitro. 2018. PMID: 29427706
Commercial biomarker assays: friend and foe.
Fischer SK, Carrasco-Triguero M, Hong K, Good J, Davancaze T, Nguy T, Li J, Darbonne W, Morimoto A, Zhu Y. Fischer SK, et al. Among authors: zhu y. Bioanalysis. 2016 Nov;8(22):2351-2362. doi: 10.4155/bio-2016-0183. Epub 2016 Oct 5. Bioanalysis. 2016. PMID: 27704870
39 results